Plain-English translation of NCT04683250 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called that targets cancer cells with a specific RET gene change. The study has two parts: first, doctors will find the safest and most effective dose of this medication, and then they will test how well it works in patients with advanced lung cancer and other solid tumors that have RET gene abnormalities.
Many advanced cancers have a RET gene mutation that drives their growth, and current treatment options are limited. This medication is designed to specifically block the RET protein, potentially stopping cancer cells from growing and offering a new treatment option for patients who need it.
You likely qualify if…
You likely don't qualify if…
In the first part of the trial, small groups of patients will receive gradually increasing doses of the medication to find the safest dose. In the second part, larger groups will receive the recommended dose to see how well it works. You will visit the clinic regularly for blood tests, scans to measure your tumors, and check-ups. The exact schedule depends on which part of the trial you join, but expect ongoing monitoring to track how you respond to the treatment and manage any side effects.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
United States